TheraGenetics Closes £3M Series A Financing
Pursues Commercialisation of Pharmacogenetic Diagnostic Tests for PatientResponse Prediction in CNS Disorders
11-Jul-2007 -
TheraGenetics Ltd announced the successful completion of a £3 million
Series A venture financing round. Swarraton Partners led the financing with
participation from Tudor Capital, IP Venture Fund, IP Group plc's venture
capital fund which was raised in partnership with the European ...
Alzheimer's disease
CNS disorders
CNS drugs
+5